AIM:To analyze and discuss the clinical effects of intravitreal ranibizumab for severe proliferative diabetic retinopathy.

METHODS:The selected 120 patients(120 eyes)with severe proliferative diabetic retinopathy from May 2012 to May 2015 in our hospital were divided into observation group and control group, according to the condition of the disease and the patients' will, 60 cases(60 eyes)in each group. The patients in two groups underwent preoperative ultrasound examination, ultrasound biomicroscopy, fundus photography, tonometry examination and some other ophthalmologic examination. All patients underwent vitrectomy. On this basis, patients in the observation group accepted injection of ranibizumab. The control group only accepted vitrectomy.

RESULTS:The effective rate of observation group was 80.0%, that of the control group was 61.7%. The difference between the two groups was statistically significant(P<0.05). IOP of the observation group was 14.96±3.53mmHg, LogMAR BCVA was 0.82±0.21 after treatments. IOP of the control group was 15.04±3.84mmHg, LogMAR BCVA was 1.05±0.22. There was no significant difference on IOP between the two groups(P>0.05). LogMAR BCVA of the two groups were different compared with those before the treatment and the difference of observation group was more significant(P <0.05). There were significant differences in the two groups after the treatment on concentration of inflammatory cytokines,and the difference was statistically significant(P<0.05).

CONCLUSION:The effect of intravitreal injection of ranibizumab for severe proliferative diabetic retinopathy is significant, worthy of promotion.